Shenzhen University General Hospital
35
12
14
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 35 trials
100.0%
+13.5% vs industry average
6%
2 trials in Phase 3/4
0%
0 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (35)
Bugitinib Combined With Venetoclax and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
Role: lead
Observational Study on Dynamic Changes of Blood Pressure During Post-epileptic Seizure Stage (OCBPS)
Role: collaborator
Efficacy and Safety of CD19/CD20 CAR/TRuC-T in Relapsed/Refractory B-Cell Lymphoma
Role: lead
Palmitoleic Acid Combined With Infliximab for Promoting Intestinal Mucosal Healing in Crohn's Disease
Role: collaborator
Akkermansia Muciniphila Combined With Infliximab for Promoting Intestinal Mucosal Healing in Crohn's Disease
Role: collaborator
Phase I Clinical Study of Haplo-HSCT Combined With Hypoxic 3D-Cultured Umbilical Cord MSC for the Treatment of SAA
Role: collaborator
Comparison of Cumulative Opioid Consumption Between Variable-Rate Feedback Infusion and Fixed-Rate Basal Infusion Modes of Intravenous PCA Following Mixed Surgery
Role: collaborator
Efficacy and Safety of MSLN CAR-T in Advanced Malignant Tumors
Role: lead
The Association Between Core Temperature and Health
Role: collaborator
Comparing the TDTP-RECIST With RECIST 1.1 and Other Volumetric Evaluation Methods for Assessing the Therapeutic Efficacy of Irregular Malignant Tumors
Role: collaborator
Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors
Role: collaborator
Treatment of Relapsed or Refractory t(8; 21) AML With Targeted AML1-ETO Neoantigen Cytotoxic T Cells (CTL)
Role: collaborator
Efficacy and Safety of CD19CD20-CAR.p40-T in B-cell Lymphoma
Role: lead
Colloid Infusion for Optimal Outcomes In Non-cardiac Surgery (COIN Trial)
Role: collaborator
The Role and Mechanism of TCR-T Cells in Immunotherapy for Acute Myeloid Leukemia
Role: lead
BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple Myeloma
Role: lead
Treatment of Relapsed or Refractory Epstein-Barr Virus Positive T-cell Lymphoma With hNeo-T
Role: collaborator
Comparing Astragalus Plus Gemcitabine to Gemcitabine Alone as Neoadjuvant Treatment for Pancreatic Cancer Patients
Role: lead
Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
Role: collaborator
Study of GPC-3 CAR-T Cells in Treating With Hepatocellular Carcinoma
Role: lead